Complement C5a des-Arg, Human

Toxicity: Standard Handling (A)

Native, human des-Arg C5a complement component. Single chain glycopeptide composed of 73 amino acids. Once the C5a glycopeptide has been produced in human plasma or serum, it is rapidly converted to C5a des-Arg upon removal of the C-terminal arginine by the endogenous serum carboxypeptidase N. Unlike the C3a des-Arg peptide, C5a des-Arg retains significant levels of its biological activities. Thus, C5a des-Arg has been shown to exhibit inflammatory cell chemotaxis, smooth muscle contraction, and leukotriene release from guinea pig lung.

Webster, R.O., et al. 1980. Immunopharmacology 1, 201.
McCarthy, K. and Henson, P.M. 1979. J. Immunol. 123, 2511.

Please refer to vial label for lot-specific concentration.

In 120 mM NaCl, 10 mM HEPES, pH 7.2.

Following initial thaw, aliquot and freeze (-70°C).

Prepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany